Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315164 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ALMNACYP2C19 | |
| SCHEMBL11951038 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ALMNACYP2C19 | |
| SCHEMBL14601299 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ALMNACYP2C19 | |
| SCHEMBL2534767 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ALMNACYP2C19 | |
| SCHEMBL1315418 | 0.79 | CACNA1G (0.51) | SMN1; SMN2MEN1KMT2ALMNACYP19A1 | |
| SCHEMBL1318530 | 0.79 | MEN1 (0.39) | SMN1; SMN2MEN1KMT2ALMNACYP19A1 | |
| SCHEMBL1317448 | 0.76 | CACNA1G (0.56) | CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL13446662 | 0.76 | CACNA1G (0.56) | CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL22854374 | 0.75 | CACNA1G (0.40) | SMN1; SMN2MEN1KMT2ALMNACYP3A4 | |
| SCHEMBL7662572 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161277-B1 | Asymmetric synthesis of peptides | UNIV READING (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-8399612-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2012-07-26 | — | — | US | disclosed |
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2011-11-10 | — | — | US | disclosed |
| US-8044173-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044173-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2011-10-25 | — | — | US | disclosed |
| EP-2161277-A2 | Asymmetric synthesis of peptides | University of Reading (GB) | 2010-03-10 | — | — | EP | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | SMN1; SMN2 3395/4885MEN1 1231/4885KMT2A 2379/4885 |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | SMN1; SMN2 3395/4885MEN1 1231/4885KMT2A 2379/4885 |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | SMN1; SMN2 3395/4885MEN1 1231/4885KMT2A 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.